Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)

2018 ◽  
Author(s):  
Todd A. Fehniger ◽  
Brian T. Hess ◽  
Veronika Bachanova ◽  
Michelle Becker-Hapak ◽  
Ethan McClain ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Anti Cd20

A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 8524-8524 ◽  
Author(s):  
Owen A. O'Connor ◽  
Changchun Deng ◽  
Jennifer Effie Amengual ◽  
Mazen Y. Khalil ◽  
Marshall T. Schreeder ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Phase I Trial ◽  
Prior Exposure ◽  
Non Hodgkin Lymphoma ◽  
Anti Cd20

scholarly journals CD20 antibodies: type II to tango?

Blood ◽  
2012 ◽  
Vol 119 (22) ◽  
pp. 5061-5063 ◽  
Author(s):  
Marinus H. J. van Oers
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Type Ii ◽  
Non Hodgkin Lymphoma ◽  
Anti Cd20 ◽  
Intense Research ◽  
Cd20 Antibodies

Although the chimeric anti-CD20 monoclonal antibody (mAb) rituximab has revolutionized the treatment of B-cell non-Hodgkin lymphoma (NHL), still many patients relapse and an increasing number become refractory to rituximab-containing therapy. This has initiated intense research to develop more potent anti-CD20 antibodies.

Anti-CD20 Monoclonal Antibody (Rituximab) for Therapy of Mediastinal CD20-Positive Large B-Cell Non-Hodgkin Lymphoma with a Local Tumor Extension into the Lung of a 10-Year-Old Girl

2003 ◽  
Vol 20 (4) ◽  
pp. 339-344 ◽  
Author(s):  
Srdjana Čulić ◽  
Vida Čulić ◽  
Visnja Armanda ◽  
Dubravka Kuljiš ◽  
Valdi Pešutić-Pisac ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Local Tumor ◽  
Tumor Extension ◽  
Non Hodgkin Lymphoma ◽  
Anti Cd20 ◽  
Large B Cell

scholarly journals A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

2013 ◽  
Vol 19 (13) ◽  
pp. 3659-3670 ◽  
Author(s):  
Razelle Kurzrock ◽  
Peter M. Voorhees ◽  
Corey Casper ◽  
Richard R. Furman ◽  
Luis Fayad ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibody ◽  
Phase I ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Castleman Disease ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Non Hodgkin Lymphoma

scholarly journals Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

2009 ◽  
Vol 15 (20) ◽  
pp. 6446-6453 ◽  
Author(s):  
Stephen M. Ansell ◽  
Sara A. Hurvitz ◽  
Patricia A. Koenig ◽  
Betsy R. LaPlant ◽  
Brian F. Kabat ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Phase I Study ◽  
Non Hodgkin Lymphoma

scholarly journals Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

Haematologica ◽  
2014 ◽  
Vol 99 (11) ◽  
pp. 1738-1745 ◽  
Author(s):  
T. E. Witzig ◽  
M. B. Tomblyn ◽  
J. G. Misleh ◽  
E. A. Kio ◽  
R. M. Sharkey ◽  
...  
Keyword(s):  
Phase I ◽  
Hodgkin Lymphoma ◽  
Phase I Study ◽  
Non Hodgkin Lymphoma ◽  
Anti Cd20

scholarly journals A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

2017 ◽  
Vol 177 (2) ◽  
pp. 243-253 ◽  
Author(s):  
Ahmed Sawas ◽  
Charles M. Farber ◽  
Marshall T. Schreeder ◽  
Mazen Y. Khalil ◽  
Daruka Mahadevan ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Lymphocytic Leukaemia ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Lymphocytic Leukaemia ◽  
Phase 1 ◽  
Non Hodgkin Lymphoma ◽  
Anti Cd20

Elevation of Activated Platelet-Dependent Chemokines in Patients With Anti-CD20 Monoclonal Antibody (Rituximab)−Treated Non-Hodgkin's Lymphoma

2007 ◽  
Vol 13 (2) ◽  
pp. 206-212 ◽  
Author(s):  
Shosaku Nomura ◽  
Kazuyoshi Ishii ◽  
Yuka Kamitsuji ◽  
Nobuhiko Uoshima ◽  
Emiko Ishikawa ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
T Cell ◽  
Hodgkin Lymphoma ◽  
Immunosorbent Assay ◽  
Stromal Cell ◽  
Enzyme Linked Immunosorbent Assay ◽  
Non Hodgkin Lymphoma ◽  
Before And After ◽  
Stromal Cell Derived Factor ◽  
Anti Cd20

.ocn.ne.jp. This study measured and compared levels of some chemokines in patients with rituximab-treated non-Hodgkin lymphoma because they may participate in the mechanism of efficacy of rituximab in non-Hodgkin lymphoma patients. Monocytic chemotactant protein-1, RANTES (regulated on activation, normally T-cell expressed and secreted), eotaxin, interleukin-8, neutrophil-activating protein-78, stromal cell-derived factor-1, and growth-regulating oncogene-α in patients with rituximab-treated non-Hodgkin lymphoma were measured by enzyme-linked immunosorbent assay. Levels of RANTES were higher in non-Hodgkin lymphoma patients than in controls. Levels of monocytic chemotactant protein-1, RANTES, and neutrophil-activating protein-78 were significantly elevated before and after chemotherapy with rituximab treatment. However, the level of stromal cell-derived factor-1 did not exhibit a significant change. Before to after chemotherapy without rituximab treatment, all chemokine levels did not exhibit significant changes. These findings suggest that activated platelet-dependent chemokines such as RANTES and neutrophil-activating protein-78 may modulate the efficacy of rituximab in antibody-dependent cellular cytotoxity.

Sign in / Sign up

Export Citation Format

Share Document